Peanut allergy rates in young children drop by 43 percent

Peanut allergy rates among children under the age of three have fallen by roughly 43 percent over the past decade, according to a study released in October 2025.

The data suggests that a shift in feeding recommendations has contributed to the reduction in diagnosis. New studies indicate that introducing peanut products to infants between four and six months of age can significantly reduce the risk of developing a peanut allergy.

Medical professionals have long advised parents to avoid peanut products for young children. However, the recent findings suggest that this cautious approach may have been counterproductive. The new evidence points toward earlier introduction as a protective factor.

The decline in allergy rates was reported in a study published in October 2025. The research highlights the specific age window of four to six months as a critical period for exposure. This timing aligns with emerging clinical guidance on introducing allergenic foods.

The findings were presented on the Aging Untold program, which covers health topics for older adults and their families. The show also featured a discussion on how aging and illness affect intimacy for couples.

Sam Cradduck, a gerontologist, spoke on the episode about the challenges couples face after a diagnosis. She noted that determining the cause of a change in sexual health is the first step. Competence and consent were identified as the primary considerations in these situations.

Dr. Rhea Rogers, a board-certified physician, addressed physical issues such as erectile dysfunction. She stated that doctors can often assist with these concerns. Rogers also clarified that intimacy and sexuality are distinct concepts, a distinction often lost in medical discussions.

The program also examined the role of older adults in clinical trials. Rogers emphasized that participants should understand the specific question a trial aims to answer before enrolling. She noted that many people view clinical trials as a last resort, but the primary benefit is early access to new treatments.

Rogers said, “You get great access to tomorrow’s medicines today, devices, therapies and other things that will not be available to everybody else for years.” Amy O’Rourke, an aging expert, added that participants must be aware they might receive a placebo.

The segment concluded with a profile of Flo Meiler, a 91-year-old track and field athlete from Vermont. Meiler began competing at age 60 and currently holds two world records. She said, “I’m sad that I can’t jump like I used to, but I really enjoy it.”